Rendering

Component: (Network and Table)
Network
138 - Disclosure - Share-Based Compensation (Tables)
(http://www.AmetekInc.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001037868 (http://www.sec.gov/CIK)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
 
Total Share-Based Compensation Expense

Total share-based compensation expense was as follows for the years ended December 31:

 

     2016     2015     2014  
     (In thousands)  

Stock option expense

    $ 9,984     $ 10,955     $ 9,130  

Restricted stock expense

      12,046       12,807       10,741  
  

 

 

    

 

 

    

 

 

  

Total pre-tax expense

      22,030       23,762       19,871  

Related tax benefit

      (6,846 )      (7,623 )      (6,154 ) 
  

 

 

    

 

 

    

 

 

  

Reduction of net income

    $ 15,184     $ 16,139     $ 13,717  
  

 

 

    

 

 

    

 

 

  

 

  
Weighted Average Assumptions Used for Estimating Fair Values of Stock Options Granted

The following weighted average assumptions were used in the Black-Scholes-Merton model to estimate the fair values of stock options granted during the years indicated:

 

     2016     2015     2014  

Expected volatility

      21.8 %      22.3 %      23.9 % 

Expected term (years)

      5.0        5.0        5.0   

Risk-free interest rate

      1.23 %      1.58 %      1.63 % 

Expected dividend yield

      0.77 %      0.69 %      0.45 % 

Black-Scholes-Merton fair value per stock option granted

    $ 9.14      $ 10.89      $ 12.21   
  
Summary of Stock Option Activity and Related Information

The following is a summary of the Company’s stock option activity and related information for the year ended December 31, 2016:

 

     Shares     Weighted
Average
Exercise
Price		      Weighted
Average
Remaining
Contractual
Life		      Aggregate
Intrinsic
Value		  
     (In thousands)            (Years)      (In millions)  

Outstanding at the beginning of the year

      5,659      $ 39.49         

Granted

      1,471        46.97         

Exercised

      (713 )      25.72         

Forfeited

      (329 )      49.40         

Expired

      (77 )      52.52         
  

 

 

          

Outstanding at the end of the year

      6,011      $ 42.25         3.9       $ 45.9   
  

 

 

    

 

 

     

 

 

     

 

 

  

Exercisable at the end of the year

      3,209      $ 36.39         2.5       $ 42.1   
  

 

 

    

 

 

     

 

 

     

 

 

  
  
Summary of Nonvested Stock Option Activity and Related Information

The following is a summary of the Company’s nonvested stock option activity and related information for the year ended December 31, 2016:

 

     Shares     Weighted
Average
Grant  Date
Fair Value		  
     (In thousands)        

Nonvested stock options outstanding at the beginning of the year

      2,717      $ 10.85   

Granted

      1,471        9.14   

Vested

      (1,057 )      10.22   

Forfeited

      (329 )      10.54   
  

 

 

    

Nonvested stock options outstanding at the end of the year

      2,802      $ 10.15   
  

 

 

    

 

 

  
  
Summary of Nonvested Restricted Stock Activity and Related Information

The following is a summary of the Company’s nonvested restricted stock activity and related information for the year ended December 31, 2016:

 

     Shares     Weighted
Average
Grant  Date
Fair Value		  
     (In thousands)        

Nonvested restricted stock outstanding at the beginning of the year

      1,061      $ 46.32   

Granted

      376        46.91   

Vested

      (292 )      38.13   

Forfeited

      (126 )      48.66   
  

 

 

    

Nonvested restricted stock outstanding at the end of the year

      1,019      $ 48.59